Anhui Anke Biotechnology (Group) Co., Ltd. (SHE:300009)

China · Delayed Price · Currency is CNY

7.99

-0.15 (-1.84%)

Sep 11, 2026, 3:04 PM CST

Market Cap	13.57B -23.4%
Revenue (ttm)	2.45B -3.1%
Net Income	701.01M +6.6%
EPS	0.42 +7.2%
Shares Out	1.67B
PE Ratio	19.38
Forward PE	17.32
Dividend	0.25 (2.98%)
Ex-Dividend Date	May 29, 2026

Volume	22,730,572
Open	8.42
Previous Close	8.14
Day's Range	7.90 - 8.42
52-Week Range	7.35 - 11.52
Beta	0.36
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 26, 2026

About SHE:300009

Anhui Anke Biotechnology (Group) Co., Ltd. engages in the biopharmaceutical industry in China and internationally. It offers human growth hormone for injection under the Ansomone name; and recombinant human interferon alpha 2b lyophilized powder, liquid, and prefilled syringe for injection, as well as recombinant human interferon alpha 2b cream, eye drop, and suppository under the Anterferon name. The company provides anti-sperm antibody, semen leukocyte peroxidase staining, one-time semen processing, sperm hypo-osmotic staining, sperm life det... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2000

Employees 2,505

Stock Exchange Shenzhen Stock Exchange

Ticker Symbol 300009

Full Company Profile

Financial Performance

In 2025, SHE:300009's revenue was 2.65 billion, an increase of 4.36% compared to the previous year's 2.54 billion. Earnings were 735.19 million, an increase of 4.00%.

Financial Statements